A Phase 1B/2 Study Of The Cd123-Targeting Antibody-Drug Conjugate Pivekimab Sunirine (Imgn632) In Combination With Venetoclax (Ven) And Azacitidine (Aza) For Patients With Cd123-Positive Aml
Azacitidine;Pivekimab Sunirine;Venetoclax
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A Phase 1B/2 Study Of The Cd123-Targeting Antibody-Drug Conjugate Pivekimab Sunirine (Imgn632) In Combination With Venetoclax (Ven) And Azacitidine (Aza) For Patients With Cd123-Positive Aml ### Output: Azacitidine;Pivekimab Sunirine;Venetoclax